Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1994 3
1995 3
1996 3
1997 3
1998 2
1999 4
2000 4
2002 1
2003 4
2004 1
2005 3
2006 1
2007 2
2009 4
2010 3
2011 6
2012 7
2013 7
2014 5
2015 7
2016 7
2017 7
2018 5
2019 2
2020 3
2021 5
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 35641271

95 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial.
Ruhlmann CH, Christensen TB, Dohn LH, Paludan M, Rønnengart E, Halekoh U, Hilpert F, Feyer P, Kristensen G, Hansen O, Keefe D, Herrstedt J. Ruhlmann CH, et al. Lancet Oncol. 2016 Apr;17(4):509-518. doi: 10.1016/S1470-2045(15)00615-4. Epub 2016 Mar 4. Lancet Oncol. 2016. PMID: 26952945 Clinical Trial.
Addition of the Neurokinin-1-Receptor Antagonist (RA) Aprepitant to a 5-Hydroxytryptamine-RA and Dexamethasone in the Prophylaxis of Nausea and Vomiting Due to Radiation Therapy With Concomitant Cisplatin.
Jahn F, Riesner A, Jahn P, Sieker F, Vordermark D, Jordan K. Jahn F, et al. Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):1101-1107. doi: 10.1016/j.ijrobp.2015.04.037. Epub 2015 Apr 28. Int J Radiat Oncol Biol Phys. 2015. PMID: 26059352 Clinical Trial.
5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study.
Matsui R, Suzuki K, Takiguchi T, Nishio M, Koike T, Hayashi T, Seto T, Kogure Y, Nogami N, Fujiwara K, Kaneda H, Harada T, Shimizu S, Kimura M, Kenmotsu H, Shimokawa M, Goto K. Matsui R, et al. BMC Pharmacol Toxicol. 2020 Oct 6;21(1):72. doi: 10.1186/s40360-020-00445-y. BMC Pharmacol Toxicol. 2020. PMID: 33023657 Free PMC article.
The Efficacy of Palonosetron Plus Dexamethasone in Preventing Chemoradiotherapy-induced Nausea and Emesis in Patients Receiving Daily Low-dose Cisplatin-based Concurrent Chemoradiotherapy for Uterine Cervical Cancer: A Phase II Study.
Mitsuhashi A, Usui H, Nishikimi K, Yamamoto N, Hanawa S, Tate S, Watanabe-Nemoto M, Uno T, Shozu M. Mitsuhashi A, et al. Am J Clin Oncol. 2017 Apr;40(2):118-121. doi: 10.1097/COC.0000000000000117. Am J Clin Oncol. 2017. PMID: 25144265 Clinical Trial.
Aprepitant plus granisetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.
Oyama K, Fushida S, Kaji M, Takeda T, Kinami S, Hirono Y, Yoshimoto K, Yabushita K, Hirosawa H, Takai Y, Nakano T, Kimura H, Yasui T, Tsuneda A, Tsukada T, Kinoshita J, Fujimura T, Ohta T. Oyama K, et al. J Gastroenterol. 2013 Nov;48(11):1234-41. doi: 10.1007/s00535-012-0746-1. Epub 2013 Jan 22. J Gastroenterol. 2013. PMID: 23338487
95 results